The epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder in a US population
Open Access
- 21 December 2024
- journal article
- research article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 12 (1) , 169-179
Abstract
Objective: To define the epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder (NMOSD) in a large US health system.Methods: We completed a retrospective observational study of adult patients in the University of Colorado Health System from 1 January 2011 to 31 December 2020, using Health Data Compass (HDC), a data warehouse that combines electronic health information with claims and public health data in Colorado. We screened HDC for patients with either (1) an abnormal aquaporin‐4 IgG test or (2) any G36 ICD‐10 code. We extracted key clinical elements by chart review and confirmed diagnosis by the 2015 International Panel for NMO Diagnosis criteria. Annual incidence and prevalence rates were calculated.Results: Our population consisted of 2,475,591 individuals contributing 11,103,522.72 person‐years of observation. In total, 115 seropositive NMOSD patients were identified. The average yearly incidence was 0.22 per 100,000 person‐years. Age and sex‐adjusted prevalence (per 100,000) was 4.33, and highest among those identifying as Asian or Pacific Islander (17.72), and Black (14.74), as separately by Hispanic ethnicity (8.02). Prevalence was higher in women (6.20:1 female:male ratio). Transverse myelitis (45%) and optic neuritis (43%) were the most common presenting clinical syndromes. In total, 6% of initial presentations were characterized by short‐segment transverse myelitis without other features.Interpretation: Seropositive NMOSD incidence is higher in our cohort than many contemporary studies. Women and those identifying as Asian or Pacific Islander, Black, and Hispanic shoulder the highest burden of disease. Clinical onset with short‐segment myelitis underscores the need for serum aquaporin‐4 IgG testing in acute myelitis presentations.Keywords
Funding Information
- Horizon Therapeutics (22‐0832)
This publication has 23 references indexed in Scilit:
- Development and validation of a claims-based algorithm to identify patients with Neuromyelitis Optica Spectrum disorderJournal of the Neurological Sciences, 2024
- Clinical and epidemiological correlates of treatment change in patients with NMOSD: insights from the CIRCLES cohortJournal of Neurology, 2022
- The occurrence of myelin oligodendrocyte glycoprotein antibodies in aquaporin-4-antibody seronegative Neuromyelitis Optica Spectrum Disorder: A systematic review and meta-analysisMultiple Sclerosis and Related Disorders, 2021
- Incidence of neuromyelitis optica spectrum disorder (NMOSD) in China: A national population-based studyThe Lancet Regional Health - Western Pacific, 2020
- The clinical profile of NMOSD in Australia and New ZealandJournal of Neurology, 2020
- Epidemiology of neuromyelitis optica spectrum disorder in Denmark (1998–2008, 2007–2014)Brain and Behavior, 2019
- What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patientsJournal of Neurology, 2017
- Epidemiology of aquaporin‐4 autoimmunity and neuromyelitis optica spectrumAnnals of Neurology, 2016
- Short Myelitis Lesions in Aquaporin-4-IgG–Positive Neuromyelitis Optica Spectrum DisordersJAMA Neurology, 2015
- Epidemiology of Neuromyelitis Optica in the United StatesArchives of Neurology, 2012